Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026Blood Cancer JournalOpen Access

Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJean L. KoffEmory UniversityMLMelissa C. LarsonMayo ClinicJCJonathon B. CohenEmory University

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates treatment outcomes in relapsed/refractory large B-cell lymphoma, highlighting ongoing therapy needs.

Key Points

  • Evaluate the treatment strategies and outcomes for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
  • Analyzed treatment patterns and outcomes in 1504 patients with R/R LBCL from 2002 to 2022.
  • Evaluated relationships between second-line therapy selection and patient outcomes.
  • Included data on autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell therapy (CAR-T).
  • 64% received chemoimmunotherapy at second line with 49% complete response rate for CAR-T.
  • Median overall survival from second line was 18.3 months, improving with the introduction of CAR-T.
  • Patients unable to receive planned ASCT or CAR-T had outcomes similar to those never intended for curative therapy.

Cite This Study

Koff et al. (2026) studied this question.

synapsesocial.com/papers/6a65a551d3aea3239cd77769https://doi.org/10.1038/s41408-026-01563-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group2026
  2. 2Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post–CAR T approval era2026 · 1 citations
  3. 3Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database2025 · 3 citations
  4. 4Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy2024 · 45 citations
  5. 5Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status2025